journal
MENU ▼
Read by QxMD icon Read
search

Journal of Crohn's & Colitis

journal
https://www.readbyqxmd.com/read/28633443/nod2-genetic-variants-predispose-one-of-two-familial-adenomatous-polyposis-siblings-to-pouchitis-through-microbiome-dysbiosis
#1
Kathleen M Schieffer, Justin R Wright, Leonard R Harris, Sue Deiling, Zhaohai Yang, Regina Lamendella, Gregory S Yochum, Walter A Koltun
Background and Aims: Individuals with familial adenomatous polyposis (FAP) may undergo a total proctocolectomy with ileal pouch-anal anastomosis (IPAA) to surgically treat their disease. Inflammation of the ileal pouch, termed pouchitis, is uncommon in FAP patients but prevalent in patients who received IPAA for ulcerative colitis, a type of inflammatory bowel disease (IBD). Methods and Results: We report on two FAP siblings, living in the same household, who underwent IPAA surgery within one week of each other...
June 19, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28605520/serial-tuberculosis-screening-in-inflammatory-bowel-disease-patients-under-anti-tnf%C3%AE-therapy
#2
Cândida Abreu, Joana Afonso, Cláudia Camila Dias, Rogério Ruas, António Sarmento, Fernando Magro
Background and aims: One of the adverse effects of the tumour necrosis factor-α monoclonal antibodies for the treatment of immune-mediated inflammatory diseases is a higher propensity for tuberculosis development. The aim of this study was to explore the utility and sensitivity of serial tuberculosis screening during anti-TNFα treatment. Methods: A cohort of 46 inflammatory bowel disease patients on infliximab was prospectively recruited and followed for 26 months...
June 9, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28605483/vedolizumab-in-pediatric-inflammatory-bowel-disease-a-retrospective-multi-center-experience-from-the-paediatric-ibd-porto-group-of-espghan
#3
Oren Ledder, Amit Assa, Arie Levine, Johanna C Escher, Lissy de Ridder, Frank Ruemmele, Neil Shah, Ron Shaoul, Victorien M Wolters, Astor Rodrigues, Holm H Uhlig, Carsten Posovsky, Kaija-Leena Kolho, Christian Jakobsen, Shlomi Cohen, Dror S Shouval, Tim de Meij, Javier Martin-de-Carpi, Lisa Richmond, Jiri Bronsky, Mira Friedman, Dan Turner
Background: Vedolizumab, an anti-integrin antibody, has proven to be effective in adults with Inflammatory Bowel Disease (IBD), but the data in pediatrics are limited. We describe the short-term effectiveness and safety of vedolizumab in a European multi-center pediatric IBD cohort. Method: Retrospective review of children (2-18 years) treated with vedolizumab from 19 centers affiliated with the Paediatric IBD Porto group of ESPGHAN. Primary outcome was week 14 corticosteroid-free remission (CFR)...
June 9, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28575273/positioning-ustekinumab-in-crohn-s-disease-from-clinical-evidence-to-clinical-practice
#4
Silvio Danese, Stefanos Bonovas, Laurent Peyrin-Biroulet
Biological medicines have revolutionized the treatment of Crohn's disease (CD). Yet, the management of patients not responding to tumor necrosis factor (TNF) antagonists remains a clinical challenge. Ustekinumab is a human monoclonal antibody blocking the biological activity of interleukins 12 and 23, which regulate the immune system and immune-mediated inflammatory disorders. It has recently been approved for the treatment of adult patients with moderately to severely active CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF antagonist, or have medical contraindications to such therapies...
June 2, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28575481/occurrence-of-anaemia-in-the-first-year-of-inflammatory-bowel-disease-in-a-european-population-based-inception-cohort-an-ecco-epicom-study
#5
Johan Burisch, Zsuzsanna Vegh, Konstantinnos H Katsanos, Dimitrios K Christodoulou, Daniela Lazar, Adrian Goldis, Colm O'Morain, Alberto Fernandez, Santos Pereira, Sally Myers, Shaji Sebastian, Natalia Pedersen, Jóngerð Olsen, Kári Rubek Nielsen, Doron Schwartz, Selwyn Odes, Sven Almer, Jonas Halfvarson, Niksa Turk, Silvja Cukovic-Cavka, Inna Nikulina, Elena Belousova, Dana Duricova, Martin Bortlik, Olga Shonová, Riina Salupere, Louisa Barros, Fernando Magro, Laimas Jonaitis, Limas Kupcinskas, Svetlana Turcan, Ioannis Kaimakliotis, Karin Ladefoged, Karen Kudsk, Vibeke Andersen, Ida Vind, Niels Thorsgaard, Pia Oksanen, Pekka Collin, Giulia Dal Piaz, Alessia Santini, Ola Niewiadomski, Sally Bell, Bjørn Moum, Naila Arebi, Jens Kjeldsen, Katrine Carlsen, Ebbe Langholz, Peter Laszlo Lakatos, Pia Munkholm, Lars Ulrik Gerdes, Jens Frederik Dahlerup
Background and aims: Anaemia is an important complication of inflammatory bowel disease (IBD). The aim of this study was to determine the prevalence of anaemia and the practice of anaemia screening during the first year following diagnosis in a European prospective population-based inception cohort. Methods: Newly diagnosed IBD patients were included and followed prospectively for one year in 29 European and 1 Australian centre. Clinical data including demographics, medical therapy, surgery and blood samples were collected...
May 31, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28575325/exclusive-enteral-nutrition-therapy-in-pediatric-crohn-s-disease-results-in-long-term-avoidance-of-corticosteroids-results-of-a-propensity-score-matched-cohort-analysis
#6
Jessica Connors, Sana Basseri, Amy Grant, Nick Giffin, Gamal Mahdi, Angela Noble, Mohsin Rashid, Anthony Otley, Johan Van Limbergen
Background & Aims: Exclusive enteral nutrition (EEN) is recommended as first-line induction therapy for pediatric Crohn's disease (CD) although corticosteroids (CS) are still used commonly. Our aim was to compare short- and long-term disease outcomes of pediatric CD patients initially managed with either EEN or CS. Methods: Medical records of newly-diagnosed pediatric CD patients treated with EEN or CS as induction therapy were retrospectively reviewed. To minimize selection bias inherent in observational cohort studies, propensity analysis was carried out...
May 27, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28575290/bringing-the-mucosa-to-heal-with-vedolizumab-in-patients-with-inflammatory-bowel-disease
#7
Satimai Aniwan, Edward V Loftus
No abstract text is available yet for this article.
May 27, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28575164/genetic-mouse-models-with-intestinal-specific-tight-junction-deletion-resemble-an-ulcerative-colitis-phenotype
#8
Wolfgang Stremmel, Simone Staffer, Mathias Jochen Schneider, Hongying Gan-Schreier, Andreas Wannhoff, Nicole Stuhrmann, Annika Gauss, Hartwig Wolburg, Anne Mahringer, Alexander Swidsinski, Thomas Efferth
Background and Aims: A key pathogenetic feature of ulcerative colitis(UC) is an intrinsic low mucus phosphatidylcholine(PC) content. Recently, a paracellular transport for PC across tight junctions(TJ) was described, suggesting TJ disturbance as cause of diminished luminal PC transport. Therefore we aimed to generate mutant mice with TJ deletion to evaluate whether an UC phenotype developed. Methods: CL57BL/6 control wild-type mice were compared to mutant mice with tamoxifen-induced villin-Cre dependent intestinal deletion of kindlin 1 and 2...
May 27, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28531313/mucosal-healing-in-ulcerative-colitis-patients-treated-with-vedolizumab-patient-dose-or-duration-dependant
#9
Rui Gaspar, Rodrigo Liberal, Guilherme Macedo
No abstract text is available yet for this article.
May 22, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28525622/dietary-therapy-with-the-crohn-s-disease-exclusion-diet-is-a-successful-strategy-for-induction-of-remission-in-children-and-adults-failing-biological-therapy
#10
Rotem Sigall Boneh, Chen Sarbagili-Shabat, Heinit Yanai, Irit Chermesh, Sivan Ben Avraham, Mona Boaz, Arie Levine
Background: Loss of response (LoR) to biologics in Crohn's disease (CD) is a significant clinical problem. Dietary therapy as a treatment strategy in this setting has not been previously reported. We report the use of dietary strategies using enteral nutrition coupled with the Crohn's Disease Exclusion Diet (CDED) for LoR to infliximab or adalimumab as a single center experience. Methods: Patients with LoR to a biologic despite dose escalation or combination therapy were treated with partial enteral nutrition (PEN) by a polymeric formula and the CDED for 12 weeks...
May 19, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28525593/incidence-phenotype-and-mortality-of-inflammatory-bowel-disease-twenty-years-after
#11
Franck Carbonnel, Marie Christine Boutron
No abstract text is available yet for this article.
May 19, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28525543/fermentable-carbohydrates-fodmaps-exacerbate-functional-gastrointestinal-symptoms-in-patients-with-inflammatory-bowel-disease-a-randomised-double-blind-placebo-controlled-cross-over-re-challenge-trial
#12
Selina R Cox, Alexis C Prince, Clio E Myers, Peter M Irving, James O Lindsay, Miranda C Lomer, Kevin Whelan
Background and Aims: Preliminary evidence suggests fermentable carbohydrate restriction might ameliorate functional gastrointestinal symptoms (FGS) in quiescent inflammatory bowel disease (IBD). Our aim was to determine whether fermentable carbohydrates exacerbate FGS in quiescent IBD using a randomised, double-blinded, placebo-controlled, cross-over, re-challenge trial. Methods: Patients with quiescent IBD and FGS responsive to a low FODMAP diet were allocated to a series of 3-day fermentable carbohydrate challenges in random order (fructan, 12 g/d; galacto-oligosaccharides, GOS, 6 g/d; sorbitol, 6 g/d; and glucose placebo, 12 g/d), each separated by a standardised washout period...
May 19, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28510689/chronic-enteropathy-associated-with-slco2a1-gene-ceas-characterization-of-an-enteric-disorder-to-be-considered-in-the-differential-diagnosis-of-crohn-s-disease
#13
Naoki Hosoe, Naoki Ohmiya, Fumihito Hirai, Junji Umeno, Motohiro Esaki, Hirokazu Yamagami, Kei Onodera, Shigeki Bamba, Hiroyuki Imaeda, Shunichi Yanai, Tadakazu Hisamatsu, Haruhiko Ogata, Takayuki Matsumoto
Small intestinal ulcers include mucosal damage caused by drugs, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), infectious diseases, and idiopathic inflammatory bowel disease. Previously, a group of Japanese investigators reported an unusual and uncommon type of enteritis and referred to the condition as chronic nonspecific multiple ulcers of the small intestine (CNSU). CNSU is characterized by chronic blood and protein loss through persistent small intestinal ulcers. Recently, four candidate mutations in the solute carrier organic anion transporter family, member 2A1 (SLCO2A1) gene, encoding a prostaglandin transporter, were identified by whole-exam sequencing in patients with CNSU...
May 16, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28505293/budesonide-mmx-in-pediatric-patients-with-ulcerative-colitis
#14
Katarzyna Karolewska-Bochenek, Marcin Dziekiewicz, Aleksandra Banaszkiewicz
No abstract text is available yet for this article.
May 15, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28505231/autologous-stem-cell-transplantation-for-refractory-crohn-s-disease-is-it-time-to-take-a-long-term-view
#15
J O Lindsay
No abstract text is available yet for this article.
May 15, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28498901/ecco-escp-consensus-on-surgery-for-crohn-s-disease
#16
Willem A Bemelman, Janindra Warusavitarne, Gianluca M Sampietro, Zuzana Serclova, Oded Zmora, Gaetano Luglio, Anthony de Buck van Overstraeten, John P Burke, Christianne J Buskens, Colombo Francesco, Jorge Amil Dias, Rami Eliakim, Tomás Elosua, I Ethem Gecim, Sanja Kolacek, Jaroslaw Kierkus, Kaija-Leena Kolho, Jérémie H Lefevre, Monica Millan, Yves Panis, Thomas Pinkney, Richard K Russell, Chaya Shwaartz, Carolynne Vaizey, Nuha Yassin, André D'Hoore
No abstract text is available yet for this article.
May 11, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28486648/faecal-microbiota-transplantation-for-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis
#17
Sudarshan Paramsothy, Ramesh Paramsothy, David T Rubin, Michael A Kamm, Nadeem O Kaakoush, Hazel M Mitchell, Natalia Castaño-Rodríguez
BACKGROUND: Faecal microbiota transplantation (FMT) has been investigated as a potential treatment for inflammatory bowel disease (IBD). We thus performed a systematic review and meta-analysis assessing the effectiveness and safety of FMT in IBD. METHODS: A systematic review was conducted until Jan 2017. Studies were excluded if patients had co-infection or data was pooled across disease subtypes (ulcerative colitis (UC), Crohn's disease (CD), pouchitis). Clinical remission was established as the primary outcome...
May 9, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28486634/patient-education-in-a-14-month-randomized-trial-fails-to-improve-adherence-in-ulcerative-colitis-influence-of-demographic-and-clinical-parameters-on-non-adherence
#18
S Nikolaus, S Schreiber, B Siegmund, B Bokemeyer, E Bästlein, O Bachmann, D Görlich, U Hofmann, M Schwab, W Kruis
Background: Recent observational studies document that non-adherence to mesalamine therapy during remission is frequent. Aim: To investigate patient impact of patient education using objective assessments of adherence. Design: A 14-month randomized, prospective clinical trial of adherence to mesalamine was conducted in 248 patients with UC (CAI ≤ 9) receiving standard care (n= 122) versus a standardized patient education programme (n= 126)...
May 9, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28486626/proximal-disease-extension-in-patients-with-limited-ulcerative-colitis-a-danish-population-based-inception-cohort
#19
J Burisch, R Ungaro, I Vind, M V Prosberg, F Bendtsen, J-F Colombel, M K Vester-Andersen
Background and aims: Disease extent in ulcerative colitis (UC) is dynamic and can progress over time. Little is known about risk factors for UC extension in the era of biologics. We investigated the risk of UC extension and subsequent risk of surgery in a Danish population-based cohort. Methods: All incident UC cases in a strictly defined Copenhagen area between 2003 and 2004 were followed prospectively through 2011. Disease extension was defined as patients with limited UC (E1 or E2) at diagnosis having progressed from the initial extent by colonoscopy or surgery to E2 or extensive colitis (E3)...
May 9, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28486597/patency-capsule-safety-in-crohn-s-disease
#20
Marco Silva, Hélder Cardoso, Guilherme Macedo
No abstract text is available yet for this article.
May 9, 2017: Journal of Crohn's & Colitis
journal
journal
41775
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"